CareFusion (NYSE: CFN) reported earnings on Feb. 2. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q2), CareFusion met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted, and GAAP earnings per share grew significantly.

Margins increased across the board.

Revenue details
CareFusion logged revenue of $915 million. The 10 analysts polled by S&P Capital IQ foresaw net sales of $912.3 million. Sales were 8.7% lower than the prior-year quarter's $1 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $0.44. The 14 earnings estimates compiled by S&P Capital IQ forecast $0.43 per share on the same basis. GAAP EPS of $0.42 for Q2 were 24% higher than the prior-year quarter's $0.34 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 49.9%, 250 basis points better than the prior-year quarter. Operating margin was 16.4%, 120 basis points better than the prior-year quarter. Net margin was 10.4%, 280 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $893.5 million. On the bottom line, the average EPS estimate is $0.46.

Next year's average estimate for revenue is $3.65 billion. The average EPS estimate is $1.81.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 76 members rating the stock outperform and five members rating it underperform. Among 30 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give CareFusion a green thumbs-up, and none give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CareFusion is outperform, with an average price target of $29.08.

The healthcare investing landscape is littered with also-rans and a few major winners. Is CareFusion the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.